A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg

Exclusion Criteria

• •Subject who administered excess daily dose of antimicrobial/antibiotics in past 72 hours before receiving written consent
• •Diagnosed to have pneumonia by taking chest X-ray in past 48 hours before receiving written consent
• •Diagnosed to have infectious diseases or such diseases results in complications before receiving written consent (NOTE: Septic shock, Bronchiectasis, Lung abscess, Pneumonia, Active tuberculosis, Pulmonary malignancy, Cystic fibrosis, Empyema, Asthma)
• •Have kidney or liver diseases who correspond following criteria:
• •(i) Creatinine Clearance(CCr) \< 50 mL/min (ii) Blood Urea Nitrogen(BUN) ≥ 30 mg/dl (iii) Alanine Aminotransferase(ALT) or Aspartate Aminotransferase(AST) \> 3 x Upper Limit Normal(ULN) (iv) Total bilirubin \> 2 x ULN (v) Alkaline Phosphatase(ALP) \> 2 x ULN.
• •Organic gastrointestinal disorder having abnormal absorption problem condition in past 6 months before receiving written consent (NOTE: Active Crohn's disease, active ulcerative colitis)
• •Diagnosed to have neutropenia where absolute neutrophil count is \< 1,000cells/mm3 (NOTE: Even though subject neutrophil count is \< 1,000cells/mm3, if it is acute infection, subject maybe possible to participate)
• •Chronic Hepatitis B carrier
• •Have proof that subject is Hepatitis C carrier or have Hepatitis C antibody
• •Immunodeficiency diseases such as HIV positive, AIDS, Bone marrow transplant or leukemia
• •Have medical history of hypersensitive reaction to antibiotics of fluoroquinolones
• •Have medical history of seizure or administration of anti-seizure drug in past 1 year before receiving written consent (NOTE: Epilepsy, Convulsions, Myasthenia gravis)
• •Medical history of ventricular arrhythmia
• •Medical history of QTc prolongation or currently administering drug that delays QTc interval (NOTE: QTc prolongation means QTc interval \> 450 msec)
• •Complex infections or diseases that can effect study assessment or need long-term antibiotic treatment exceeding 7 days
• •Subject who has participated in Clinical trials or Bioequivalence test in past 30 days before receiving written consent
• •Clinically significant by observations considered as unsuitable based on medical judgement by investigators where current condition can effect quality of safety or data